secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001628280-23-028730
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q2 net loss $55.7M; WHIM NDA on track; chronic neutropenia data promising
--------------------------------------------------------------------------------

- Net loss of $55.7M in Q2 2023 includes $29.9M non-cash warrant adjustment; cash $142.3M at June 30.
- NDA submission for mavorixafor in WHIM syndrome on track for early 2H 2023; potential US approval in 1H 2024.
- Preliminary Phase 2 chronic neutropenia data: mavorixafor increased ANC and enabled G-CSF dose reductions in 3 patients.
- Raised ~$65M via PIPE in May 2023; post-quarter expanded debt facility to $115M with $22.5M initial drawdown.
- Appointed Dr. Christophe Arbet-Engels as Chief Medical Officer; new mavorixafor composition-of-matter patent through 2038.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/0001628280-23-028730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023028730/xfor-20230810.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer